EGFR and non-small cell lung carcinoma: This is just a fraction of the total cfDNA in blood, but this analyte can be analyzed to identify tumor driver mutations that can be therapeutically targeted, such as mutations in epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) that are currently used in the clinic (12).